These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38652976)

  • 1. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
    Ruf T; Kramer R; Forschner A; Leiter U; Meier F; Reinhardt L; Dücker P; Ertl C; Tomsitz D; Tietze JK; Gutzmer R; Dabrowski E; Zimmer L; Gesierich A; Zierold S; French LE; Eigentler T; Amaral T; Heinzerling L
    Eur J Cancer; 2024 May; 203():114028. PubMed ID: 38652976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors.
    Tomsitz D; Ruf T; Zierold S; French LE; Heinzerling L
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
    Ertl C; Ruf T; Mentzer D; Kong M; Kramer R; Bergwelt-Baildon MV; Subklewe M; Tomsitz D; Ascierto PA; Dummer R; Gogas H; Lebbé C; Long GV; McArthur G; Neilan TG; Ribas A; Robert C; Schadendorf D; Zimmer L; Eigentler T; Grabbe S; Forschner A; Kähler KC; Milani V; Pföhler C; Hassel J; Gutzmer R; Loquai C; Routy B; Furness AJS; Blank C; Wolchok JD; French LE; Hauschild A; Heinzerling L
    Eur J Cancer; 2024 Mar; 199():113505. PubMed ID: 38262306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
    JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.
    Luo J; Beattie JA; Fuentes P; Rizvi H; Egger JV; Kern JA; Leung DYM; Lacouture ME; Kris MG; Gambarin M; Santomasso BD; Faleck DM; Hellmann MD
    J Thorac Oncol; 2021 Oct; 16(10):1759-1764. PubMed ID: 34265432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers.
    Cariou PL; Pobel C; Michot JM; Danlos FX; Besse B; Carbonnel F; Mariette X; Marabelle A; Messayke S; Robert C; Routier E; Noël N; Lambotte O
    Eur J Cancer; 2024 Jun; 204():114065. PubMed ID: 38643707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective Study.
    Ruf T; Rahimi F; Anz D; Tufman A; Salzer S; Zierold S; Tomsitz D; French LE; Heinzerling L
    J Immunother; 2024 Jul-Aug 01; 47(6):227-231. PubMed ID: 38483178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Kim YJ; Lee M; Kim EH; Lee S; Park S; Hong MH; Shin SJ; Jung I; Lee CK; Lee CS
    Cancer Lett; 2024 Aug; 596():216998. PubMed ID: 38830470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events.
    Brongiel S; Rychalsky KL; Luon D; Johnson AR; Price C; Abdelghany O
    Ann Pharmacother; 2023 Feb; 57(2):148-155. PubMed ID: 35656843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor-associated gastritis: Patterns and management.
    Lin J; Lin ZQ; Zheng SC; Chen Y
    World J Gastroenterol; 2024 Apr; 30(14):1941-1948. PubMed ID: 38681126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience.
    Kitano M; Honda T; Hikita E; Masuo M; Miyazaki Y; Kobayashi M
    Asia Pac J Clin Oncol; 2024 Aug; 20(4):463-471. PubMed ID: 38608154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
    Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
    Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis.
    Paderi A; Gambale E; Botteri C; Giorgione R; Lavacchi D; Brugia M; Mazzoni F; Giommoni E; Bormioli S; Amedei A; Pillozzi S; Matucci Cerinic M; Antonuzzo L
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF in the era of immune checkpoint inhibitors: friend or foe?
    Chen AY; Wolchok JD; Bass AR
    Nat Rev Rheumatol; 2021 Apr; 17(4):213-223. PubMed ID: 33686279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.
    Camard M; Besse B; Cariou PL; Massayke S; Laparra A; Noel N; Michot JM; Ammari S; Pavec JL; Lambotte O
    Respir Med Res; 2022 Nov; 82():100969. PubMed ID: 36370683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.